News

Newsletter

WTR – Brazil: Economic success matched by a surge in counterfeiting

Please read the article titled ‘Brazil: Economic success matched by a surge in counterfeiting,’ published on WTR and authored by Rafael Lacaz and Raquel Bastos, Partner and Head of our Anti-Counterfeiting team, respectively.

The article focuses on the growth of the Brazilian market, accompanied by an increase in counterfeiting. Consequently, it is crucial to enforce intellectual property rights, a task that demands careful planning, advanced technology, intelligence, training, and coordination. This effort is supported by various laws, treaties, and constitutional, civil, criminal, and procedural codes.

Collaboration with official anti-counterfeiting agencies and financial services companies is indispensable for the successful implementation and maintenance of an anti-counterfeiting program. That’s why, at Kasznar Leonardos, our goal is to ensure that your company can actively participate in this dialogue by forming alliances or associations dedicated to combating counterfeiting. You can count on us!

Read the full article here.

Back

Last related news

9 de December de 2025

Fake Software Resellers: A Growing Risk for Users and a New Front in IP Enforcement

For years, the most common form of software piracy involved downloading cracked or unauthorized versions from websites offering them for free. Although Fake Software Resellers: A Growing Risk for Users and a New Front in IP Enforcement

  • Kasznar Leonardos
  • Ler notícia

    25 de November de 2025

    Significant Win for Kasznar Leonardos as Appellate Court Raises Compensation in Software Infringement Case

    Kasznar Leonardos is pleased to announce an important victory before the São Paulo Court of Appeals in a software license compliance action Significant Win for Kasznar Leonardos as Appellate Court Raises Compensation in Software Infringement Case

  • Kasznar Leonardos
  • Ler notícia

    13 de November de 2025

    ANVISA Publishes Exceptional Rule to Expedite Analysis of Medicines and Biological Products

    The National Health Surveillance Agency (Anvisa) published on Monday, November 10, 2025, the Collegiate Board Resolution (RDC) No. 997/2025, which institutes exceptional ANVISA Publishes Exceptional Rule to Expedite Analysis of Medicines and Biological Products

  • Kasznar Leonardos
  • Ler notícia